DOSING FOR ADULTS WITH PREVIOUSLY TREATED cGVHD

Oral, infusion-free dosing for patients

IMBRUVICA® is available in two formulations, including capsules and a single tablet, once-daily option.

Click here to see recommended dosing for pediatric patients with previously treated cGVHD. 


When a patient no longer requires therapy for the treatment of cGVHD, IMBRUVICA® should be discontinued considering the medical assessment of the individual patient

  • Administer IMBRUVICA® at approximately the same time each day with a glass of water
  • Swallow tablets or capsule whole. Do not open, break, or chew the capsules. Do not cut, crush, or chew the tablets

Missed dose1

  • If a dose of IMBRUVICA® is not taken at the scheduled time, it can be taken as soon as possible on the same day with a return to the normal schedule the following day. Do not take extra doses of IMBRUVICA® to make up for the missed dose

Once-daily dosing is necessary to ensure inhibition of BTK enzymatic activity1

IMBRUVICA® occupancy at the  BTK active site was observed for up to 24 hours with once-daily dosing^1IMBRUVICA® occupancy at the  BTK active site was observed for up to 24 hours with once-daily dosing^1

BTK=Bruton’s tyrosine kinase, cGVHD=chronic graft versus host disease.

Reference: 1IMBRUVICA® (ibrutinib) Prescribing Information.